We are excited to have published a collaborative paper with Chris French's lab at Brigham and Women's Hospital in the journal Cancer Research! We identify EZH2, a chromatin regulator that epigenetically silences genes, as a novel vulnerability in NUT carcinoma, that EZH2 suppression of tumor suppressor genes acts in parallel to the activation of oncogenes by the fusion oncoprotein BRD4-NUT, and that combined treatment of mouse models of NUT carcinoma with both an EZH2 inhibitor and a BET inhibitor potently blocks tumor growth and prolongs animal survival. Congratulations to Cate, Chris, and Quan for their contributions to the success of this project! Click here for full text and also see the spotlight commentary on the paper in Cancer Research.

Congratulations to the French Lab at Brigham and Women's Hospital and Harvard Medical School for their new paper "The BRD4–NUT Fusion Alone Drives Malignant Transformation of NUT Carcinoma"! We were happy to contribute to this story! Click here for full text.